NCT04918186 2026-02-12
IPROC
Canadian Cancer Trials Group
Phase 2 Recruiting
Clinical Trials
6 trialsNCT06769126 2026-01-22
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
SWOG Cancer Research Network
Phase 2 Recruiting
NCT06880523 2025-12-18
SLIDE-HCC
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT06441747 2025-07-29
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Australasian Gastro-Intestinal Trials Group
Phase 2 Recruiting
NCT06290505 2025-07-23
PALEO
Australasian Gastro-Intestinal Trials Group
Phase 2 Recruiting
NCT03847649 2025-06-11
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Canadian Cancer Trials Group
Phase 2 Recruiting